参考文献/References:
[1].Maron BJ,Maron MS. Hypertrophic cardiomyopathy[J]. Lancet,2013,381(9862):242-255.
[2].Ommen SR,Mital S,Burke MA,et al.2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice Guidelines[J].Circulation,2020,142(25):e558-e631.
[3].Sen-Chowdhry S,Jacoby D,Moon JC,et al.Update on hypertrophic cardiomyopathy and a guide to the guidelines[J].Nat Rev Cardiol,2016,13(11):651-675.
[4].Ingles J,Burns C, Barratt A, et al. Application of genetic testing in hypertrophic cardiomyopathy for preclinical disease detection [J]. Circ Cardiovasc Genet, 2015, 8（6）∶852-859.
[5].Zou Y,Song L,Wang Z,et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China:a population-based echocardiographic analysis of 8080 adults[J]. Am J Med,2004,116(1):14-18.
[6].Omahony C,Ellioty P M.Prevention of sudden cardiac death in hypertrophic cardiomyopathy[J].Heart,2014,100(3):254-260.
[7].中华医学会超声医学分会超声心动图学组,中国超声医学工程学会超声心动图专业委员会,肥厚型心肌病超声心动图检查规范专家共识编写组.肥厚型心肌病超声心动图检查规范专家共识[J].中华医学超声杂志(电版),2020,17(5):394-408.
[8].Borjesson M,Pelliccia A. Incidence and aetiology of sudden cardiac death in young athletes:an international perspective[J]. Br J Sports Med,2009,43(9):644-648.
[9].Elliott PM,Gimeno JR,Thaman R,et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy[J].Heart,2006,92(6):785-791.
[10].O’Mahony C,Jichi F,Pavlou M,et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD)[J]. Eur Heart J,2014,35(30):2010-2020.
[11].国家心血管病中心心肌病专科联盟,中国医疗保健国际交流促进会心血管病精准医学分会,“中国成人肥厚型心肌病诊断与治疗2023”专家组.中国成人肥厚型心肌病诊断与治疗指南2023[J].中国循环杂志,2023,38(1):1-33.
[12].Maron MS,Rowin EJ,Wessler BS,et al. Enhanced American College of Cardiology American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy[J]. JAMA Cardiol,2019,4(7):644-657.
[13].Rowin EJ,Maron BJ,Carrick RT,et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction[J]. J Am Coll Cardiol,2020,75(24):3033-3043.
[14].Sadoul N,Prasad K,Elliott PM,et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy[J].Circulation,1997,96(9):2987-2991.
[15].Elliott PM,Gimeno JR,Tomé MT,et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy[J]. Eur Heart J,2006,27(16):1933-1941.
[16].Wang J,Wang Y,Zou Y,et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy[J]. Eur J Heart Fail,2014,16(9):950-957.
[17].Zou Y,Wang J,Liu X,et al. Multiple gene mutations,not the type of mutation,are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy[J]. Mol Biol Rep,2013,40(6):3969-3976.
[18].Masri A,Pierson LM,Smedira NG,et al. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography[J]. Am Heart J,2015,169(5):684-692.e1.
[19].Lu X,Wang W,Zhu L,et al. Prognostic significance of fragmented QRS in patients with hypertrophic cardiomyopathy[J]. Cardiology,2017,138(1):26-33.
[20].李艳兵,毛俊,闫倩,等.肥厚型心肌病患者标准12导联体表心电图J点抬高与心脏骤停的关系[J].临床心血管病杂志,2015,31(2):133-136.
[21].Wang Y,Tang Y,Zou Y,et al. Plasma level of big endothelin-1 predicts the prognosis in patients with hypertrophic cardiomyopathy[J]. Int J Cardiol,2017,243:283-289.
[22].Zhu L,Wang J,Wang Y,et al. Plasma uric acid as a prognostic marker in patients with hypertrophic cardiomyopathy[J]. Can J Cardiol,2015,31(10):1252-1258.
[23].Zhu L,Zou Y,Wang Y,et al. Prognostic significance of plasma high-sensitivity C-reactive protein in patients with hypertrophic cardiomyopathy[J]. J Am Heart Assoc,2017,6(2):e004529.
[24].Wang Y,Wang J,Zou Y,et al. Female sex is associated with worse prognosis in patients with hypertrophic cardiomyopathy in China[J]. PLoS One,2014,9(7):e102969.
[25].Shirotani S,Minami Y,Saito C,et al. B-type natriuretic peptide and outcome in patients with apical hypertrophic cardiomyopathy[J]. J Cardiol,2020,76(4):357-363.
[26].Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCE/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines[J]. J Thorac Cardiovase Surg, 2011, 142(6):e153-e203.
[27].Elliott PM,Anastasakis A,Borger MA,et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J,2014,35(39):2733-2779.
[28].Zeppenfeld K,Tfelt-Hansen J,de Riva M,et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death[J]. Eur Heart J,2022,43(40):3997-4126.
[29].Cardim N,Galderisi M,Edvardsen T,et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy:an expert consensus of the European Association of Cardiovascular Imaging endorsed by the Saudi Heart Association[J]. Eur Heart J Cardiovasc Imaging,2015,16(3):280.
[30].Maron BJ,Desai MY,Nishimura RA,et al. Management of hypertrophic cardiomyopathy:JACC state-of-the-art review[J]. J Am Coll Cardiol,2022,79(4):390-414.
[31]. Liu J ,Wu G,Zhang C,et al.Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy [J].Heart Rhythm,2020,17(10):1658-1663.
[32].Dong Y,Yang W,Chen C,et al. Validation of the 2020 AHA/ACC risk stratification for sudden cardiac death in Chinese patients with hypertrophic cardiomyopathy[J]. Front Cardiovasc Med,2021,8:691653.
[33].Maron BJ,Rowin EJ,Casey SA,et al. Risk stratification and outcomeof patients with hypertrophie cardiomyopathy≥60 years of age[J]. Circulation, 2013,127(5):585-593.
[34].Maron BJ,Nishimura RA,Maron MS. Shared decisionmaking in HCM[J]. Nat Rev Cardiol,2017,14(3):125126.
[35].Nistri S,Olivotto I,Maron MS,et al. β blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy [J] Am J Cardiol,2012,110(5):715-719.
相似文献/References:
[1]冯坤,刘春霞,熊峰,等.超声心动图在肥厚型心肌病诊治中的应用进展[J].心血管病学进展,2016,(4):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
FENG Kun,LIU Chunxia,XIONG Feng,et al.Progress in Application of Echocardiography in
Diagnosis and Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2016,(2):409.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.021]
[2]张耀庭 李烽 朱永翔 陆丽洁 龙明智.沙库巴曲/缬沙坦在室性心律失常中的研究进展[J].心血管病学进展,2019,(7):982.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.004]
ZHANG Yaoting,LI Feng,ZHU Yongxiang,et al.Research Progress of Sacubitril/Valsartan in Ventricular Arrhythmia[J].Advances in Cardiovascular Diseases,2019,(2):982.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.004]
[3]黄淮滨 刘甲兴.肥厚型心肌病治疗新靶点——钙脱敏治疗[J].心血管病学进展,2019,(7):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
HUANG HuaibinLIU Jiaxing.A Novel Target for Therapy in Hypertrophic Cardiomyopathy: Ca2+ desensitizer[J].Advances in Cardiovascular Diseases,2019,(2):1047.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.021]
[4]马秀英 贾锋鹏.肥厚型心肌病并发心房颤动的危险因素研究进展[J].心血管病学进展,2020,(12):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
MA XiuyingJIA Fengpeng.Update about the Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(2):1243.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.005]
[5]邓清文,何森.肥厚型心肌病合并心房颤动的研究进展[J].心血管病学进展,2021,(4):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
DENG Qingwen,HE Sen.Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(2):27.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.010]
[6]尚依一 刘罗 庞明杰 张艳.基因检测在肥厚型心肌病中的应用进展[J].心血管病学进展,2021,(6):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
SHANG Yiyi,LIU Luo,PANG Mingjie,et al.Gene Detection for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):512.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.009]
[7]王娟 杨艳敏.肥厚型心肌病发生缺血性卒中的危险因素和管理策略研究进展[J].心血管病学进展,2021,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
WANG Juan,YANG Yanmin.Risk Factors and Management Strategies of Ischemic Stroke in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):582.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.002]
[8]武志刚 孙佳莉 王巍.基于心脏磁共振成像的肥厚型心肌病患者早期峰值充盈率与舒张功能相关性的研究[J].心血管病学进展,2021,(7):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
WU Zhigang,SUN Jiali,WANG Wei.Correlation Between Early Peak Filling Rate and Diastolic Function in Patients with Hypertrophic Cardiomyopathy Based on Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2021,(2):658.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.020]
[9]蓝庆肃 武锋超 马兰虎 韩冰 徐金 彭瑜 张钲.Mavacamten治疗肥厚型心肌病的研究进展[J].心血管病学进展,2021,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
LAN Qingsu,WU Fengchao,MA Lanhu,et al.Mavacamten in Treatment of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(2):1028.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
[10]李传伟,罗浩,曾春雨.肥厚型心肌病室间隔消减策略的研究进展[J].心血管病学进展,2022,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]
LI Chuanwei,LUO Hao,ZENG Chunyu.Septal Reduction Therapy of Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2022,(2):7.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.002]